PMID- 35744079
OWN - NLM
STAT- MEDLINE
DCOM- 20220627
LR  - 20220716
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 58
IP  - 6
DP  - 2022 Jun 17
TI  - Current and Future Approaches in Management of Chronic Spontaneous Urticaria 
      Using Anti-IgE Antibodies.
LID - 10.3390/medicina58060816 [doi]
LID - 816
AB  - Chronic spontaneous urticaria (CSU) considerably alters patients' quality of 
      life, often for extended periods, due to pruriginous skin lesions, impaired 
      sleep, unexpected development of angioedema, and failure of conventional 
      treatments in properly controlling signs and symptoms. Recent research focused on 
      the development of new therapeutic agents with higher efficacy. Although the 
      production of specific immunoglobulin E (IgE) antibodies against certain 
      allergens is not a characteristic of the disease, treatment with omalizumab, a 
      monoclonal anti-IgE antibody, proved efficient and safe in patients with moderate 
      to severe chronic spontaneous urticaria uncontrolled by H1-antihistamines. 
      Ligelizumab, a high-affinity monoclonal anti-IgE antibody, may also efficiently 
      relieve symptoms of unresponsive chronic urticaria to standard therapies. This 
      comprehensive review aims to present recently acquired knowledge on managing 
      chronic spontaneous urticaria with new anti-IgE antibodies. We conducted 
      extensive research on the main databases (PubMed, Google Scholar, and Web of 
      Science) with no restrictions on the years covered, using the search terms 
      "anti-IgE antibodies", "omalizumab", "ligelizumab", and "chronic spontaneous 
      urticaria". The inclusion criteria were English written articles, and the 
      exclusion criteria were animal-related studies. ClinicalTrials.gov was also 
      reviewed for recent relevant clinical trials related to CSU treatment. CSU is a 
      challenging disease with a significant effect on patients' quality of life. 
      Current therapies often fail to control signs and symptoms, and additional 
      treatment is needed. New biologic therapies against IgE antibodies and FcepsilonRIalpha 
      receptors are currently under investigation in advanced clinical trials. We 
      reviewed recently published data on CSU management using these novel treatments. 
      The development of new and improved treatments for CSU will lead to a more 
      personalized therapeutical approach for patients and provide guidance for 
      physicians in better understanding disease mechanisms. However, some agents are 
      still in clinical trials, and more research is needed to establish the safety and 
      efficacy of these treatments.
FAU - Orzan, Olguta Anca
AU  - Orzan OA
AD  - Dermatology Department, "Carol Davila" University of Medicine and Pharmacy, 
      011461 Bucharest, Romania.
AD  - Dermatology Department, "Elias" University Emergency Hospital, 011461 Bucharest, 
      Romania.
FAU - Popa, Liliana Gabriela
AU  - Popa LG
AD  - Dermatology Department, "Carol Davila" University of Medicine and Pharmacy, 
      011461 Bucharest, Romania.
AD  - Dermatology Department, "Elias" University Emergency Hospital, 011461 Bucharest, 
      Romania.
FAU - Mihai, Mara Madalina
AU  - Mihai MM
AUID- ORCID: 0000-0002-1436-0088
AD  - Dermatology Department, "Carol Davila" University of Medicine and Pharmacy, 
      011461 Bucharest, Romania.
AD  - Dermatology Department, "Elias" University Emergency Hospital, 011461 Bucharest, 
      Romania.
FAU - Cojocaru, Anca
AU  - Cojocaru A
AD  - Dermatology Department, University of Medicine and Pharmacy of Craiova, 200349 
      Craiova, Romania.
FAU - Giurcaneanu, Calin
AU  - Giurcaneanu C
AD  - Dermatology Department, "Carol Davila" University of Medicine and Pharmacy, 
      011461 Bucharest, Romania.
AD  - Dermatology Department, "Elias" University Emergency Hospital, 011461 Bucharest, 
      Romania.
FAU - Dorobantu, Alexandra Maria
AU  - Dorobantu AM
AUID- ORCID: 0000-0002-7752-7930
AD  - Dermatology Department, "Elias" University Emergency Hospital, 011461 Bucharest, 
      Romania.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220617
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (anti-IgE antibodies)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Animals
MH  - *Anti-Allergic Agents/therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Chronic Disease
MH  - *Chronic Urticaria/drug therapy
MH  - Humans
MH  - Immunoglobulin E
MH  - Omalizumab/therapeutic use
MH  - Quality of Life
MH  - *Urticaria/drug therapy
PMC - PMC9227249
OTO - NOTNLM
OT  - anti-IgE antibodies
OT  - chronic spontaneous urticaria
OT  - ligelizumab
OT  - omalizumab
COIS- The authors declare no conflict of interest.
EDAT- 2022/06/25 06:00
MHDA- 2022/06/28 06:00
PMCR- 2022/06/17
CRDT- 2022/06/24 01:28
PHST- 2022/05/05 00:00 [received]
PHST- 2022/06/02 00:00 [revised]
PHST- 2022/06/14 00:00 [accepted]
PHST- 2022/06/24 01:28 [entrez]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/06/28 06:00 [medline]
PHST- 2022/06/17 00:00 [pmc-release]
AID - medicina58060816 [pii]
AID - medicina-58-00816 [pii]
AID - 10.3390/medicina58060816 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2022 Jun 17;58(6):816. doi: 10.3390/medicina58060816.